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Naturally derived regulatory T cells (Treg cells) 
are generated in the thymus and play a pivotal 
role  in  preventing  pathological  immune  re-
sponses including autoimmunity, inflammation, 
and  allergy  (Sakaguchi  et  al.,  2008).  Foxp3,  a 
member of the forkhead transcription factors, 
has been identified as the master regulator for the 
development and function of Treg cells (Zheng 
and  Rudensky,  2007).  Deficiencies  in  Foxp3 
cause  a  lethal  lymphoproliferative  disorder  in 
scurfy mice and are associated with immuno-
dysregulation, polyendocrinopathy, enteropathy, 
and X-linked syndrome in humans. A study using 
Foxp3-GFP reporter mice revealed that Foxp3 
expression is associated with suppressor activity 
irrespective of CD25 expression (Fontenot et al., 
2005). Finally, the maintenance of Foxp3 expres-
sion in mature Treg cells is needed to sustain the 
transcriptional and functional program established 
during Treg cell development. These findings 
demonstrate that Foxp3 acts as a Treg cell lineage 
specification  factor,  programming  the  develop-
ment and the suppressive activity of Treg cells.
Thymic differentiation of Treg cells is in-
structed by the intensity of signaling via the TCR 
and  is  regulated  by  co-stimulatory  receptors 
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CD4+ regulatory T cells (Treg cells) expressing the transcription factor Foxp3 play a pivotal 
role in maintaining peripheral tolerance by inhibiting the expansion and function of patho-
genic conventional T cells (Tconv cells). In this study, we show that a locus on rat chromo-
some 9 controls the size of the natural Treg cell compartment. Fine mapping of this locus 
with interval-specific congenic lines and association experiments using single nucleotide 
polymorphisms (SNPs) identified a nonsynonymous SNP in the Vav1 gene that leads to the 
substitution of an arginine by a tryptophan (p.Arg63Trp). This p.Arg63Trp polymorphism is 
associated with increased proportion and absolute numbers of Treg cells in the thymus and 
peripheral lymphoid organs, without impacting the size of the Tconv cell compartment. This 
polymorphism is also responsible for Vav1 constitutive activation, revealed by its tyrosine 
174 hyperphosphorylation and increased guanine nucleotide exchange factor activity. 
Moreover, it induces a marked reduction in Vav1 cellular contents and a reduction of Ca2+ 
flux after TCR engagement. Together, our data reveal a key role for Vav1-dependent T cell 
antigen receptor signaling in natural Treg cell development.
© 2011 Colacios et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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from F1 rats receiving BN bone marrow cells (Fig. 1 E). 
Thus, the difference in size of the Treg cell compartment be-
tween LEW and BN rats is controlled by factors that are in-
trinsic to hematopoietic cells.
Fort1, a 117-kb locus on chromosome 9, controls the size 
of the natural Treg cell population
We previously identified a 17-cM interval on chromosome   
9 (c9) that controls the size of the CD45RClowCD4+ popula-
tion in BN and LEW strains (Subra et al., 2001). Because 
Foxp3+ T cells were restricted to this population (Fig. S1), we 
reasoned that the genetic control of the Treg cell population 
such as CD28 and cytokines, including IL-2 (Josefowicz and 
Rudensky, 2009). TCR signaling controls Treg cell and con-
ventional T cell (Tconv cell) development differently. Treg cell 
development is favored under conditions of TCR signaling 
with high strength that promotes negative selection of Tconv 
cell (Jordan et al., 2001; Hsieh et al., 2004; Carter et al., 2005). 
In addition, deficiency of several pleiotropic signaling mole-
cules,  including TAK1, Bcl10, CARMA1, PKC-, IKK-,   
c-Rel, LAT, and Foxo1/Foxo3a proteins, severely impairs 
Treg cell development, whereas it only marginally affects Tconv 
cell development (Koonpaew et al., 2006; Wan et al., 2006; 
Gupta et al., 2008; Medoff et al., 2009; Ouyang et al., 2010). 
However, the signaling pathways precisely involved in Treg 
cell development remain poorly characterized.
Vav1 is a key signal transducer downstream of the TCR 
and is mandatory for the development and activation of   
T cells (Turner and Billadeau, 2002; Tybulewicz, 2005). In the 
present study, we demonstrate a major role for Vav1 protein 
in natural Treg cell development. The analysis of the genetic 
factors responsible for the difference in the size of the Treg cell 
compartment between two rat strains led to the identification 
of a nonsynonymous polymorphism in the first exon of Vav1, 
responsible for the substitution of an arginine by a tryptophan 
at position 63 (p.Arg63Trp or R63W). Associated with this 
substitution, we observed an increased proportion and abso-
lute  numbers  of  Treg  cells  in  peripheral  lymphoid  organs, 
which most likely result from an increased output of Treg cells 
from the thymus. The Vav1-W63 variant is constitutively ac-
tive, and its cellular protein levels are markedly reduced. This 
is associated with a decrease in Ca2+ mobilization under TCR 
activation. Thus, our study highlights the importance of Vav1 
in Treg cell development and the role that Vav1 signaling   
alterations could play in susceptibility to immune diseases.
RESULTS AND DISCUSSION
Brown Norway (BN) rats have higher proportions  
and absolute numbers of CD4+Foxp3+ Treg cells  
than Lewis (LEW) rats
We investigated CD4+Foxp3+ Treg cell development in LEW 
and BN rats, two strains which differ strikingly in their sus-
ceptibility to immune diseases (Fournié et al., 2001). Flow 
cytometry analysis of CD4+Foxp3+ T cells in PBMCs, LNs, 
and spleen revealed that the proportion (Fig. 1 A) and abso-
lute numbers (Fig. 1 B) of Foxp3+ cells among CD4+ T cells 
were significantly higher in BN than in LEW rats. Similar   
results were observed in double-positive (DP) CD4+CD8+ 
and  single-positive  (SP)  CD4+CD8  thymocytes  (Fig.  1,   
C and D), suggesting that these differences were probably   
acquired early during thymic ontogeny. To assess whether this 
difference was intrinsic to hematopoietic cells or caused by 
extrinsic factors, hematopoietic progenitor cells from either 
LEW or BN bone marrow were differentiated in the same 
thymic (LEW × BN) F1 environment. Although similar lev-
els of chimerism were achieved in (LEW × BN) F1 recipients 
regardless of the donor origin, higher percentages of CD4+ 
Foxp3+ donor T cells were found in PBMCs, LNs, and spleen 
Figure 1.  BN and LEW rats exhibit different proportions and num-
bers of natural Foxp3+ Treg cells. (A) Representative flow cytometry 
profiles of Foxp3+ T cells in CD4+-gated lymphocytes in PBMCs, LNs, and 
spleen from LEW and BN rats. The values on each cytometry profile repre-
sent the mean percentages of Foxp3+ cells in the CD4+ T cell population 
(mean ± SEM; n = 4). Data are representative of four independent experi-
ments. (B) Absolute numbers (mean ± SEM) of Foxp3+CD4+ cells in the 
LNs and spleen from BN (n = 6) and LEW (n = 10) rats. (C) Representative 
flow cytometry profiles of Foxp3 expression in DP CD4+CD8+ and SP 
CD4+CD8 thymocytes from naive BN and LEW rats. The value on each 
profile represents the percentages of Foxp3+ thymocytes (mean ± SEM;  
n = 6). (D) Absolute numbers of Foxp3+ cells in DP CD4+CD8+ and SP CD4+ 
thymocytes from BN (n = 6) and LEW (n = 6) rats. Bars represent the 
means ± SEM. Data are representative of three independent experiments. 
(E) Percentages of Foxp3+ cells among CD4+ T cells of donor origin in 
PBMCs, LNs, and spleen originating from (LEW × BN) F1 recipients of bone 
marrow from BN or LEW rats 14 wk after engraftment. Bars represent the 
mean ± SEM (n = 6 rats per group). Data are representative of two inde-
pendent experiments. **, P < 0.01.JEM Vol. 208, No. 11  2185
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might also be located in this interval. Using a panel of BN 
congenic lines and sublines for various LEW genomic regions 
of c9 (BN.LEWc9), we identified an interval of 117 kb that 
exerts a major effect on the proportion of CD4+Foxp3+  
T cells (Fig. 2, A and B). Indeed, although the size of the   
Treg cell population was unchanged in BN.LEWc9-C, -H, 
and -Be congenic lines when compared with BN rats, it was 
markedly reduced in BN.LEWc9-Ia, -B, -Bc, and -Bf con-
genic lines, reaching values close to those found in LEW rats. 
Results were similar when CD4+Foxp3+ T cells were ana-
lyzed in the LN, spleen, or thymus (unpublished data). In 
contrast, this locus, named Fort1 for Foxp3+ Treg cell locus 1, 
did not influence the size of the conventional CD4+Foxp3 
compartment (Fig. S2). We then tested whether Fort1 had an 
impact on the suppressive function of the Foxp3+CD4+ T cells 
using an in vitro assay. Purified CD4+CD25+ T cells from 
BN and Bf rats did not proliferate when cultured with allo-
geneic T cell–depleted APCs, indicating that they are anergic 
(Fig. 2 C). Importantly, they suppressed the proliferation of 
naive CD4+ T cells from (LEW × BN) F1 rats with similar 
efficacy, thus showing that the in vitro suppressive potential 
of Treg cells is independent of the genomic origin of Fort1 
(Fig. 2 D). Moreover, by using LEW.BNc9 and DA.BNc9 
congenics (LEW or Dark Agouti [DA] congenic rats for BN 
Fort1) and BN-1L rats (BN rats congenic for LEW MHC), 
we further demonstrated that the control of Fort1 on the size 
of the Treg cell compartment was independent of the genetic 
background and MHC haplotype (Fig. S3). Thus, the 117-kb 
Fort1 region contains a gene, or a set of genes, that exerts a 
pivotal control on the size of the Treg cell compartment.
Vav1 R63W polymorphism is associated with the difference 
in the size of the Treg cell compartment
Physical and high-density marker genetic maps of the 117-kb 
Fort1 region were constructed using Celera and NCBI Rat 
Genome databases. We identified four genes within Fort1: C3 
(Complement 3 precursor), Gpr108 (G protein–coupled receptor 108), 
Trip10/Cip4 (Cdc42-interacting protein 4), and Vav1 (Fig. 2 B). 
Because we did not find any differences in messenger RNA 
(mRNA) expression of these four genes between LEW, BN, 
and BN.LEWc9-Bf CD4 T cells (Fig. S4), we investigated 
differences in single nucleotide polymorphisms (SNPs) by   
sequencing their coding regions. The 15 SNPs identified 
were then genotyped in the smallest congenic line (Bf) and   
in four additional rat strains (DA, Piebald Virol Glaxo [PVG], 
Biobreeding [BB], and August Copenhagen Irish [ACI]). No 
polymorphism was found in the Trip10 gene, and the poly-
morphisms found in Gpr108 were synonymous, thus render-
ing improbable the involvement of these genes (Table I). 
Conversely, identification of two nonsynonymous SNPs in 
C3 and Vav1 made them strong candidates for the control of 
Treg cell development. Vav1 appeared to be the strongest can-
didate gene because it is specifically expressed in hemato-
poietic cells (Katzav et al., 1989), and Fort1 control is intrinsic 
to hematopoietic cells (Fig. 1 E), whereas C3 is mainly pro-
duced is the liver (Alper et al., 1969). A further argument for 
Figure 2.  Fort1, a 117-kb locus of chromosome 9, controls the 
proportion of CD4+Foxp3+ Treg cell and Vav1 protein expression. 
(A) Percentages of Foxp3+ cells among blood CD4+ T cells from the BN 
parental strain and a series of BN.LEWc9 congenic lines and sublines. 
Each point represents the value found in individual rats (n = 4–9).  
(B) Genetic maps of congenic lines. Microsatellite markers are indicated 
on the left. Black, white, and gray segments indicate chromosomal re-
gions of BN, LEW, or undetermined origin, respectively. On the right is 
shown the physical map of the Fort1 117-kb region constructed using 
information from the Celera Genomics genome assembly available in 
the NCBI Rat Genome Resource, which contains four genes, C3, Gpr108, 
Trip10, and Vav1. (C) BN (closed) or Bf (open) CD25+ and CD25 FACS 
sorted T cells were cultured for 3 d with allogeneic APCs. Proliferation 
was assessed with an 18-h [3H]thymidine pulse added after 48 h  
of culture. Data represent mean ± SEM. (D) Suppressor activity of 
CD4+CD25+ Treg cells was measured by T cell proliferation assay. Treg cells 
from BN or Bf were co-cultured with effector T cells (CD4+CD45RChigh 
from F1 rats) at various ratios of Treg cell/Teff cell. The proliferation level 
of responder cells alone was assigned a value of 100%. Results are rep-
resentative of two independent experiments. (E) Western blot analysis 
of Vav1 protein expression in thymic and LN CD4+ T cell lysates from 
LEW, BN, and Bf rats. (F) Western blot analysis of VAV1 protein in 
HEK293 cells transfected with plasmids encoding human wild-type 
VAV1 (VAV1-R63), mutated VAV1 (VAV1-W63), or oncogenic VAV1 
(VAV1-CH). (E and F) -Actin was used as a loading control. In each 
case, results show one blot of a representative experiment and a graph 
representing the mean ± SEM of three to six independent experiments. 
**, P < 0.01; ns, not significant.2186 Vav1 controls regulatory T cells development | Colacios et al.
VAV1-W63 (mutated), or the oncogenic human VAV1 
(VAV1-CH)  that  lacks  the  first  67  N-terminal  amino   
acids and is known to be constitutively active. The protein 
levels of VAV1 were lower in HEK293 cells transfected with 
VAV1-W63 when compared with that of HEK293 cells trans-
fected with VAV1-R63 (Fig. 2 F). A similar observation was 
made in HEK293 cells transfected with plasmids coding for rat 
Vav1 variants (unpublished data). The decreased VAV1 pro-
tein expression is also found in HEK293 cells transfected with 
VAV1-CH (Fig. 2 F). Thus, these data show that the Vav1 
R63W polymorphism impacts the cellular content of Vav1 
and  suggest  that  the  Vav1-W63  variant  might  share  bio-
chemical and functional properties with the constitutively ac-
tive VAV1-CH.
Vav1 R63W polymorphism influences Vav1 functions
Vav1 functions as a guanine exchange factor (GEF) for small 
GTPases, thereby facilitating their transition from an inactive 
(GDP bound) to an active (GTP bound) state. Vav1 is also an 
adaptor molecule that participates in protein–protein inter-
actions. After TCR engagement, Vav1 is rapidly phosphory-
lated, in particular in tyrosine 174 (Tyr174), which is crucial to 
Vav1 activities (Aghazadeh et al., 2000; López-Lago et al., 2000). 
To analyze the impact of Vav1 R63W polymorphism on 
Vav1 functions, we first performed biochemical experiments 
in HEK293 cells transfected with plasmids coding for human 
VAV1-R63 (wild type), VAV1-W63 (mutated), or the consti-
tutively active VAV1 (VAV1-CH). Both VAV1-W63 and 
excluding the involvement of the C3 nonsynonymous poly-
morphism is based on the haplotypic mapping conducted in 
six rat strains and in the BN.LEWc9-Bf congenic because the 
percentage of Foxp3+CD4+ T cells found in the BB rats is 
similar to that found in all the tested strains except the BN 
strain (Table I). Thus, the c.244C>T SNP in exon 1 of Vav1 
is the only SNP that correlates with the Treg cell phenotype. 
This SNP results in the substitution of an arginine (R) by a 
tryptophan (W) in BN Vav1 at position 63 in the N-terminal 
calponin homology (CH) domain (p.Arg63Trp or R63W). 
Altogether, these results strongly suggest that the Vav1 R63W 
polymorphism  plays  a  prominent  role  in  the  control  of 
Foxp3+CD4+ T cells, in the absence of involvement of the 
three other genes present in the 117-kb interval.
The Vav1 R63W polymorphism controls Vav1 cellular 
protein levels
We next analyzed the impact of the Vav1 R63W polymor-
phism on Vav1 protein expression. We used rat CD4+ T cells 
expressing the Vav1-W63 (BN rats) or the Vav1-R63 (LEW 
and BN.LEWc9-Bf rats) variants. Immunoblotting revealed 
that levels of Vav1 were markedly lower in thymic and pe-
ripheral BN CD4+ T cells (Fig. 2 E). The same difference was 
also observed in CD4+CD25+ (Treg cells) and in CD4+CD25 
(Tconv cells; Fig. S5). To test whether the reduced Vav1 protein 
expression is the direct consequence of the R63W polymor-
phism, we performed experiments in HEK293 cells transfected 
with  plasmids  coding  for  human VAV1-R63  (wild  type), 
Table I.  Vav1 variants control the percentage of CD4+Foxp3+ Treg cells
Gene Exon/nucleotide Protein Genotypes
BN LEW Bfb DA PVG BB ACI
C3 Ex2/c.205 C>T p.= T C C C C T C
C3 Ex9/c.1018 T>C p.= C T T T C C C
C3 Ex11/c.1252 C>T p.= T C C C C T C
C3 Ex12/c.1339 T>C p.= C T T T C C C
C3 Ex12/c.1369 T>C p.= C T T T C C C
C3 Ex23/c.2929 G>A p.= A G G G G A G
C3 Ex32/c.4109 A>G p.Thr1356Ala G A A A A G A
Gpr108 Ex6/c.536 G>A p.= A G G G G A G
Gpr108 Ex8/c.930 T>C p.= C T T T T C T
Gpr108 Ex8/c.935 C>T p.= T C C C C T C
Gpr108 Ex13/c.1397 G>A p.= A G G G G A G
Gpr108 Ex15/c.1520 G>A p.= A G G G G A G
Trip10 NP NP NP NP NP NP NP NP NP
Vav1a Ex1/c.244 C>Ta p.Arg63Trpa T C C C C C C
Vav1 Ex5/c.579 C>T p.= C T T T C T T
Vav1 Ex6/c.627 G>A p.= A G G G A G G
NP, no polymorphism. Genes listed are found in the 117-kb interval. The Exon/nucleotide column indicates SNPs found in exons. The exon number and the position of the SNP 
in the cDNA of the gene are given. The Protein column indicates the effect of the SNP (p.= indicates a synonymous mutation without effect on the primary structure of the 
protein; when the SNP is nonsynonymous, the position and the amino acid substitution according to the nucleotide mutation are given). Genotypes of BN type or similar to 
BN genotype are in bold. Mean percentages ± SEM of CD4+Foxp3+ T cells in PBMCs (n ≥ 4) are as follows: BN, 17.0 ± 0.2%; LEW, 8.9 ± 0.9%; Bf, 11.1 ± 0.5%; DA, 10.3 ± 0.3%; 
PVG, 7.6 ± 0.2%; BB, 11.0 ± 0.2%; and ACI, 9.9 ± 0.5%.
aThis mutation in the first exon of Vav1 is the only mutation associated with the high (BN genotype) or low (other strains genotypes) percentage of CD4+Foxp3+ T cells.
bBN.LEWc9-Bf congenic line.JEM Vol. 208, No. 11  2187
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(Fig. 3 F; López-Lago et al., 2000). Together, these data 
demonstrate that the VAV1-W63 mutation leads to its con-
stitutive activation.
To analyze the impact of TCR engagement on Vav1 ac-
tivities, we also performed biochemical analysis on purified 
CD4+ T cells from BN (Vav1-W63) and BN.LEWc9-Bf 
(Vav1-R63) rats. In agreement with our results on HEK293 
cells, we showed that Vav1 in BN CD4+ T exhibits an in-
creased global phosphorylation on Vav1 tyrosines (Fig. 4 A) 
and Tyr174 (Fig. 4 B) as compared with Bf CD4+ T cells, 
both at basal state and after TCR engagement. However, the 
activation of Rac1 (Fig. 4 C) and RhoA (Fig. 4 D) GTPases 
was modest as compared with transfected HEK293 cells ex-
pressing similar levels of Vav1 protein. These data suggest 
that the increased Vav1-W63 activity in the CD4+ T cells 
might be counterbalanced by the decrease in Vav1 protein 
amount, thus maintaining GEF activity close to physiological 
levels. Using confocal microscopy, we next showed that   
localization and recruitment of Vav1-W63 to TCR-inducible 
complexes are not altered because we observed similar co-
localization of Vav1 in BN and Bf CD4+ T cells (Fig. 4 E). 
Recently, it has been shown that many critical events in-
volved in T cell activation, such as TCR-triggered Ca2+ flux, 
were mediated by a GEF-independent function of Vav1 
that can act as an adaptor (Miletic et al., 2009; Saveliev et al., 
2009). We therefore assessed the effect of R63W polymor-
phism on Ca2+ flux in thymic and peripheral CD4+ T cells. 
CD4+ T cells bearing Vav1-W63 (BN rats) had lower TCR-
induced  Ca2+  flux  than  those  bearing  Vav1-R63  (Bf  and 
LEW rats; Fig. 4 F). Together, these data show that the 
Vav1 R63W polymorphism has major consequences on 
Vav1 biochemical properties, triggering a state of constitu-
tive activation that leads to the imbalance between Vav1 
GEF-dependent (Rac1 and RhoA activation) and -independent 
(Ca2+ flux) functions.
A recent study described the process of cooperative auto-
inhibition maintaining Vav1 protein in an inactive state and 
shed light on the molecular mechanisms whereby the Vav1-
W63 variant might modify Vav1 functions (Yu et al., 2010). 
This work showed that the CH domain plays a key role in 
strengthening the interaction of the catalytic Dbl homology 
domain with a helix of the adjacent acidic domain, which 
leads to the autoinhibition of the GEF activity. This core 
inhibitory  interaction  is  relieved  by  phosphorylation  of 
Tyr174. The phosphorylation of two other tyrosines, Tyr142 
and Tyr160, modulates the CH-inhibitory helix by making 
Tyr174 more accessible to kinases. Of peculiar interest, the 
side chain of Tyr160 is in contact with Arg63 in the CH do-
main (Yu et al., 2010). Based on these data, we hypothesize 
that replacement of the basic arginine by the hydrophobic 
tryptophan in position 63 might induce a modification of the 
tertiary structure that could make Tyr174 more accessible to 
phosphorylation. This mechanism would fully account for 
the similar behavior of the Vav1-W63 and Vav1-CH vari-
ants. The activation of Vav1-W63 is associated with an ap-
proximately fourfold reduction of protein expression that 
VAV1-CH show increased phosphorylation on total tyro-
sines (Fig. 3 A) and Tyr174 (Fig. 3 B) and displayed enhanced 
GEF activity (Fig. 3 C) as compared with VAV1-R63. This 
increased GEF activity resulted in elevated activation of Rac1 
(Fig. 3 D), the VAV1 preferential downstream effectors, and 
also in a stronger activation of RhoA (17-fold compared with 
3-fold for Rac1; Fig. 3 E). Confocal examination of tran-
siently transfected HEK293 cells showed that VAV1-R63 did 
not induce major morphological changes, whereas the expres-
sion  of  VAV1-W63  induced  lamellipodia  formation  and 
pronounced rounding of the cell body as a result of actin cyto-
skeleton contractility (Fig. 3 F). These morphological changes 
are  reminiscent  of  what  was  observed  for  VAV1-CH 
Figure 3.  Biochemical analyses of VAV1 in HEK293 cells trans-
fected with VAV1 variants reveal that VAV1-W63 is constitutively 
active. (A and B) Analysis of VAV1 phosphorylation in HEK293 transfected 
with different human VAV1 plasmids. VAV1 was immunoprecipitated and 
immunoblotted with anti-phosphotyrosine 4G10 mAb (A) or anti–
phospho-VAV1 (Y174) antibody (B). After stripping, membranes were 
probed with anti-VAV1 antibody. IP, immunoprecipitation. (C) Analysis of 
GEF activity of VAV1 using pull-down with Rac1G15A agarose beads on 
serum-starved HEK293 cells transfected with different human VAV1 plas-
mids. (D and E) Analysis of Rac1 or RhoA activities in HEK293 cells trans-
fected with different VAV1 variants using pull-down assay to detect 
relative amounts of Rac1-GTP (D) or RhoA-GTP (E). Total Rac1 and RhoA 
levels were used as loading controls. In each case, results show one blot 
of a representative experiment and a graph representing the mean ± SEM 
of three to four independent experiments. WB, Western blot. (F) Confocal 
analysis of HEK293 cells transfected with different VAV1 variants. Actin 
was visualized with phalloidin–Alexa Fluor 488. Representative images  
of three independent experiments are shown. *, P < 0.05; **, P < 0.01;  
ns, not significant.2188 Vav1 controls regulatory T cells development | Colacios et al.
might maintain Vav1 GEF activity close to normal levels 
but would impact Vav1 GEF-independent functions as re-
vealed by the reduction of Ca2+ flux. Together with a recent 
study showing that Vav1 GEF activity is not required for 
the development of CD4+CD25+ T cells (Saveliev et al., 
2009), these observations suggest that Vav1-W63 could in-
fluence Treg cell development through an effect on Vav1 
GEF-independent functions.
The link between the Vav1-W63 variant and the devel-
opment of the Treg cells remains unknown. The size of the 
Treg cell compartment can be altered through modulations   
of the strength of TCR signals. For example, enrichment in 
Treg cells was observed when TCR signaling was enhanced by 
the loss of the tyrosine phosphatase SHP-1, a negative regula-
tor of TCR-mediated signaling (Carter et al., 2005). Enrich-
ment was also observed when developing T cells were exposed 
to their cognate peptides with high-avidity interactions (Jordan 
et al., 2001; van Santen et al., 2004; Cabarrocas et al., 2006). 
Thus, in rats carrying the Vav1-W63 variant, the increased 
development of Treg cells might result from Vav1-W63– 
dependent modifications in signaling pathways downstream 
of the TCR.
Given the link existing between Treg cell defects and auto-
immunity (Sakaguchi et al., 2008), our findings may have im-
portant implications. We recently provided evidence that  Vav1 
R63W variants play a central role in susceptibility to experi-
mental autoimmune encephalomyelitis and impact the pro-
duction of IFN- and TNF (Jagodic et al., 2009; unpublished 
data). Our present findings suggest that this may also be re-
lated to the effect of Vav1 variants on the Treg cell compart-
ment. Thus, genetic or acquired alterations in  Vav1-dependent 
signaling could impact the susceptibility to immune-mediated 
diseases through effects on Treg cell development.
MATERIALS AND METHODS
Animals. All breeding and experimental procedures were performed in 
accordance with European Union guidelines and were approved by the 
national  and  local  ethics  committee  (license  no.  31259;  agreement  no. 
B315558). Rats were kept under specific pathogen-free conditions. LEW, 
BN, and DA rats were obtained from Centre d’Élevage Janvier (Le Genest 
St. Isle, France). (LEW × BN) F1 rats and congenic lines were produced 
in our animal facility. The BN congenic lines for LEW chromosome 9 (BN.
LEWc9) used in this study are summarized in Table S1 and were developed 
in our laboratory as described previously (Mas et al., 2004). The LEW.BNc9 
and DA.BNc9 congenic lines for BN chromosome 9 and the BN congenic 
for LEW MHC (BN-1L) were described previously (Cautain et al., 2001; 
Jagodic et al., 2009). The animals used in this study were 8–12 wk of age.
Antibodies, cell staining, and flow cytometry. The mAbs used for flow 
cytometry or purification of T cell subpopulations were as follows: W3/25 
(anti–rat CD4), OX6 (anti–rat MHC class II), OX8 (anti–rat CD8), OX12 
(anti–rat  light chain), OX22 (anti–rat CD45RC), OX39 (anti–rat CD25), 
R73 (anti–rat TCR-), V65 (anti–rat TCR-), 3.4.1 (anti–rat CD8), and 
3.2.3 (anti–rat NKR-P1). The hybridomas OX6, OX7, OX8, OX12, OX22, 
OX39, OX40, OX85, and W3/25 were provided by D. Mason (University 
of Oxford, Oxford, England, UK), and the hybridomas JJ319, V65, and R73 
were provided by T. Hünig (University of Würzburg, Würzburg, Germany). 
The mAbs used for flow cytometry were fluorochrome conjugates either pre-
pared in our laboratory or purchased from BD and eBioscience. The biotinyl-
ated mAbs 42-3-7 (RT1-An haplotype) and 163-7F3 (RT1-Al haplotype) were 
Figure 4.  In primary CD4 T cells, Vav1 R63W polymorphism  
affects Vav1 phosphorylation, Rac1/RhoA GTPases activities, and 
Ca2+ flux under TCR stimulation. (A and B) Analysis of Vav1 phosphory-
lation by immunoblot with anti-phosphotyrosine 4G10 mAb (A) or anti–
phospho-Vav1(Y174) antibody (B) in BN (Vav1-W63) and Bf (Vav1-R63) LN 
CD4+ T cells stimulated (stim) or not (unstim) with anti-TCR mAb. Lysates 
were probed with anti-Vav1Ab. IP, immunoprecipitation. (C and D) Analy-
sis of Rac1 or RhoA activation in serum-starved BN and Bf CD4+ T cells 
stimulated or not with anti-TCR mAb using pull-down assay to detect the 
relative amounts of Rac1-GTP (C) or RhoA-GTP (D). Total Rac1 and RhoA 
levels were used as loading controls. In each case, results show one blot 
of a representative experiment and a graph representing the mean ± SEM 
of three to five independent experiments. WB, Western blot. (E) Confocal 
microscopy analyses of CD4+ T cells of BN and Bf rats that were stimu-
lated or not with anti-TCR mAb. Cells were staining for TCR (red) and 
Vav1 (green) using the appropriate second reagents. Line scan analysis 
indicates the distribution of the TCR and Vav1 along the white lines. Rep-
resentative images of three independent experiments are shown. (F) Analy-
sis of Ca2+ influx in purified CD4+ T cells from LEW, BN, and Bf LNs (left) 
or thymus (middle) loaded with Indo-1 and incubated with an anti-TCR 
mAb. Analyses were first performed in the absence of rabbit anti–mouse 
(RAM) immunoglobulin cross-linker to measure the baseline Ca2+ level in 
unstimulated CD4+ T cells. Flow was halted for the addition of 50 µg/ml 
RAM (first arrow). The increase in intracellular Ca2+ flux was then recorded 
in real time over 200 s. Cell flow was again halted for the addition of 
ionomycin (Iono; second arrow) to measure the maximal signal from the 
Indo-1 indicator. Data are representative of three independent experi-
ments involving a total of five or six rats per strain. These data are ex-
pressed in the right panel as percentages of the variation of maximum 
Ca2+ flux observed in the Bf congenic subline compared with the BN (left) 
and LEW (right) parental strains.JEM Vol. 208, No. 11  2189
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Real-time PCR was performed on LC480 (Roche) using the PCR SYBR 
green kit (Roche). The relative amount of mRNA in each sample was cal-
culated as the ratio between the target mRNA and the corresponding   
endogenous control GAPDH mRNA.
Ca2+ flux. CD4+ T cells or CD4+ SP thymocytes were loaded at 37°C for 
30 min with the fluorescent Ca indicator Indo-1 (Invitrogen) at 5 µM. The 
cells were then washed and incubated with 10 µg/ml anti-TCR mAb (R73) 
at 37°C for 15 min. Ca influx was measured by flow cytometry on an LSRII. 
Baseline levels were measured for 50–100 s, at which time rabbit anti–mouse 
(Sigma-Aldrich) was added at 50 µg/ml as a cross-linker. Events were re-
corded for an additional 150–200 s. Finally, ionomycin was added at 2 µg/ml 
to all samples to verify Indo-1 labeling. Relative Ca concentrations were 
measured as the ratio between the Ca-bound dye and the Ca-free dye. Data 
were analyzed using FlowJo software.
Immunoblotting and immunoprecipitation. Vav1 protein expression 
and phosphorylation were analyzed on lysates from rat CD4+ T cells or from 
HEK293 cells 20 h after transfection with 2 µg of human wild-type VAV1-
R63, the mutated VAV1-W63, or oncogenic VAV1-CH plasmids. In 
some experiments, rat CD4+ T cells were stimulated with anti-TCR mAb 
(R73) used at 10 µg/ml and rabbit anti–mouse at 50 µg/ml for 1 min at 37°C. 
Total cellular proteins were extracted with ice-cold lysis buffer containing 
10 mM Tris HCl, 1% Triton X-100, a cocktail of protease inhibitors (Com-
plete Mini, EDTA-free; Roche), 50 mM NaF, 1 mM Na3VO4, and 1 mM 
DTT.  For  immunoprecipitation,  clarified  homogenates  were  incubated 
overnight at 4°C with the antibodies and a mix of protein A/G Sepharose 
beads. After washes, proteins were eluted with Laemmli buffer and analyzed 
by SDS-PAGE followed by Western blotting on Immobilon-P membranes 
(Millipore) with appropriate antibodies (Vav-1 antibody, clone D7 [Santa 
Cruz Biotechnology, Inc.]; -actin antibody, clone AC-15 [Sigma-Aldrich]; 
phosphotyrosine  antibody,  clone  4G10  [Millipore];  and  phosphotyrosine 
174 of Vav1 antibody [Santa Cruz Biotechnology, Inc.]). Immunoreactive 
bands were detected by chemiluminescence with the SuperSignal detection 
system (Thermo Fisher Scientific). Band intensities were quantified using the 
Scion Image software.
GTPase pull-down assays. HEK293 cells were transfected with 1 µg of 
wild-type VAV1-R63 or 2 µg of mutated VAV1-W63 or 2 µg of oncogenic 
VAV1-CH. 3 h after transfection, cells were serum-starved overnight be-
fore being processed. The amounts of GTP-bound active Rac1 or RhoA 
were determined by GST pull-down assay. Cells were lysed in ice-cold lysis 
buffer (50 mM Tris-base, pH 7.4, 500 mM NaCl, 10 mM MgCl2, 2.5 mM 
EGTA, 1% Triton X-100, 0.5% Na deoxycholate, 0.1% SDS, 50 mM NaF, 
1 mM Na3VO4, and a tablet of protease and phosphatase inhibitors), and 
clarified lysates were incubated with 30 µg GST-PBD (PAK1-binding do-
main for Rac1) or GST-RBD (Rhotekin-binding domain for RhoA) bound 
to glutathione Sepharose at 4°C for 30 min. Beads were washed with 50 mM 
Tris-base, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 5 mM EGTA, 1% Triton 
X-100, and GTP-bound GTPases eluted with Laemmli buffer and subjected 
to SDS-PAGE followed by Western blotting. Active VAV1 was purified   
using the nucleotide-free mutant Rac1G15A (Cell Biolabs Inc.), which dis-
plays a strong affinity for active GEFs (García-Mata et al., 2006). VAV1 was 
detected by Western blotting using VAV1 antibody (D7 clone; Santa Cruz 
Biotechnology, Inc.) on pull-down cell extracts.
Immunofluorescence staining. Freshly isolated CD4 T cells were incu-
bated for 15 min with 10 µg/ml mouse anti–rat TCR at 4°C. CD4 T cells 
were then stimulated or not with 50 µg/ml goat anti–mouse IgG for 15 min. 
Cells were fixed with 4% paraformaldehyde and plated on 0.5 mg/ml poly-
dl-ornithine (Sigma-Aldrich) for 15 min. Upon washing with PBS, cells were 
permeabilized with 0.1% Triton X-100, saturated with 1% BSA, and incubated 
with antibody against Vav1 (1:200 dilution; Santa Cruz Biotechnology, Inc.) for 
20 min at room temperature. Secondary antibodies used were Alexa Fluor 
594–conjugated  streptavidin  and Alexa  Fluor  488–conjugated  anti–rabbit 
provided by H. Kunz (University of Pittsburgh, Pittsburgh, PA). Foxp3 intra-
cellular expression was detected using an APC-labeled anti–mouse/rat Foxp3 
Staining Set from eBioscience according to their standard protocol. Data were 
collected on FACSCalibur or LSRII cytometers (BD) and analyzed using 
FlowJo or Cell Quest software package (BD).
Bone marrow chimeras. (LEW × BN) F1 rats were lethally irradiated 
(950 rads) 1 d before bone marrow transplantation. Recipient rats were 
given 108 viable nucleated bone marrow cells intravenously. 14 wk after en-
graftment, the PBMCs, spleen, and LNs were analyzed for T cells of donor 
or recipient origin by using RT1-A haplotype–specific mAbs and for expres-
sion of Foxp3 in CD4+ T cells of donor origin.
Purification of T cell subsets. Rat CD4+ T cells were negatively selected 
from LN and spleen cells by using a cocktail of the following mAbs: OX6, 
OX8, OX12, 3.2.3, and V65. After washing and incubating with anti–mouse 
IgG magnetic microbeads (Invitrogen), CD4+ T cells were purified by mag-
netic depletion. Both OX8 and W3/25 were added to the cocktails for the 
purification of a non–T cell fraction that included B cells and monocytes/
macrophages. SP CD4+ thymocytes T cells were negatively selected from 
thymus using OX8 mAb and anti–mouse IgG magnetic microbeads. The 
purity of CD4+ T cells was >92%. For Treg cell purification, negatively 
selected CD4+ T cells were stained with 341-FITC (anti–rat CD8), R73-
APC (anti–rat TCR-), W3/25-PB (anti–rat CD4), and OX39-PE (anti–rat 
CD25) and were electronically sorted using a FACSAria II-Sorp (BD). The 
purity of the cells was >99%.
Proliferative responses and Treg cell suppression assays. For Treg cell 
suppression assays, purified (LEW × BN) F1 CD4+CD45RChigh T cells 
(105/well) were stimulated with irradiated allogeneic APCs (0.5 × 105/well; 
T cell–depleted splenocytes from DA rats) alone or in the presence of de-
creased numbers of FACS-sorted BN or Bf CD4+CD25+ Treg cells and cul-
tured in 96-well plates for 72 h. Proliferation was analyzed by [3H]thymidine 
incorporation during the last 18 h.
Sequencing. The sequencing templates were amplified from genomic DNA, 
and the sequencing reactions were performed using the BigDye terminator 
version 3.1 (Applied Biosystems) Products were separated and recorded on an 
ABI 3100 (Applied Biosystems). Sequences were analyzed with Vector NTI 
software (InforMax). SNPs identified by comparing LEW and BN coding se-
quences and untranslated regions of all genes in the region of 117 kb were sub-
sequently typed in additional rat strains using the same procedures.
Plasmids, DNA constructs, mutagenesis, and transfection. Experi-
ments were performed using human VAV1 to benefit from the availability 
of a positive control, the oncogenic human VAV1 (VAV1-CH) that lacks 
the first 67 N-terminal amino acids (VAV1-CH) and is known to be con-
stitutively active. pEF-VAV1-myc plasmid encoding either human VAV1 
cDNA or oncogenic human VAV1 was described previously (Deckert et al., 
1996). The mutation in human VAV1 at the position c.244C>T (R63W) of 
the sequence coding for the R63W substitution was introduced by site- 
directed mutagenesis using the QuikChange II XL Site-Directed Mutagene-
sis kit (Agilent Technologies) according to the manufacturer’s instructions. 
Mutation was introduced using the following primers: forward, 5-GAGG-
TCAACCTGtGGCCCCAGATGTCCC-3; and reverse, 5-GGGACATC-
TGGGGCCaCAGGTTGACCTCA-3. The lower case letters indicate the 
mutations. The nucleotide sequence of each construct was verified by DNA 
sequencing. HEK293 fibroblasts were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% FCS. HEK293 cells were trans-
fected using Effectene (QIAGEN) according to the manufacturer’s instruc-
tions. Experiments were performed 20 h after transfection.
Relative quantification of mRNAs by real-time quantitative RT-
PCR. Total RNA was extracted by the RNeasy mini kit (QIAGEN). RT 
was  performed  using  Superscript  III  Reverse  transcription  (Invitrogen). 2190 Vav1 controls regulatory T cells development | Colacios et al.
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